Provectus Biopharmaceuticals, Inc.
PVCT
Rank in Stocks
#26783
Provectus Biopharmaceuticals, Inc. is a clinical-stage biotechnology firm... Provectus Biopharmaceuticals, Inc. is a clinical-stage biotechnology firm dedicated to pioneering immunotherapy treatments. These therapies are grounded in its proprietary halogenated xanthene platform. Among its key developments is PV-10, an experimental autolytic cancer immunotherapy. This treatment is being explored for a range of adult solid tumor malignancies, encompassing melanoma and various gastrointestinal cancers (such as hepatocellular carcinoma, metastatic colorectal cancer to the liver, metastatic neuroendocrine tumors to the liver, and metastatic uveal melanoma to the liver). It also targets pediatric solid tumors, including neuroblastoma, Ewing sarcoma, rhabdomyosarcoma, and osteosarcoma. Additionally, Provectus is advancing oral formulations of pharmaceutical-grade rose bengal sodium (cGMP RBS) to combat a broad spectrum of conditions. These include adult solid tumors (such as head and neck, breast, testicular, and colorectal cancers), pediatric blood cancers like leukemia, acute respiratory syndromes such as coronavirus, infections caused by multi-drug resistant bacteria (specifically Gram-negative bacteria), and certain ocular conditions, notably infectious keratitis. Furthermore, the company is progressing PH-10, an investigational immuno-dermatology agent designed to address inflammatory skin conditions like psoriasis and atopic dermatitis. Originally established in 2002, the company was initially named Provectus Pharmaceuticals, Inc., before rebranding as Provectus Biopharmaceuticals, Inc. in December 2013. Its operations are headquartered in Knoxville, Tennessee.
Share Price
$0.0425
Last synced: 2026-11-13
Market Cap
$17.86M
Change (1 day)
0.00%
Change (1 year)
-30.33%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Provectus Biopharmaceuticals, Inc. (PVCT)
Category
Healthcare
EPS for Provectus Biopharmaceuticals, Inc. (PVCT)
EPS as of September 2026 TTM: $-0.01
According to Provectus Biopharmaceuticals, Inc.'s latest financial reports, its current EPS (TTM) is $-0.01. At the end of 2025 the company had an EPS of $-0.01, equal to its 2024 EPS of $-0.01.
EPS history for Provectus Biopharmaceuticals, Inc. from 2000 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-0.01 | 12.00% |
| 2025 | $-0.01 | 14.16% |
| 2024 | $-0.01 | 52.70% |
| 2023 | $-0.01 | -12.94% |
| 2022 | $-0.01 | -46.54% |
| 2021 | $-0.02 | -20.50% |
| 2020 | $-0.02 | 0.00% |
| 2019 | $-0.02 | -6.10% |
| 2018 | $-0.02 | -41.80% |
| 2017 | $-0.04 | -63.40% |
| 2016 | $-0.10 | -23.08% |
| 2015 | $-0.13 | 122.98% |
| 2014 | $-0.06 | -72.24% |
| 2013 | $-0.21 | 90.91% |
| 2012 | $-0.11 | -38.89% |
| 2011 | $-0.18 | -25.00% |
| 2010 | $-0.24 | 14.29% |
| 2009 | $-0.21 | 5.00% |
| 2008 | $-0.20 | -9.09% |
| 2007 | $-0.22 | -4.35% |
| 2006 | $-0.23 | -62.90% |
| 2005 | $-0.62 | 100.00% |
| 2004 | $-0.31 | -16.22% |
| 2003 | $-0.37 | -58.43% |
| 2002 | $-0.89 | -41.45% |
| 2001 | $-1.52 | 4,305.80% |
| 2000 | $-0.03 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $-0.89 | 7,846.43% |
US
|
|
| $15.66 | -139,921.43% |
US
|
|
| $-7.07 | 63,025.00% |
US
|
|
| $-5.29 | 47,132.14% |
AU
|
|
| $12.73 | -113,780.36% |
BE
|
Questions about Provectus Biopharmaceuticals, Inc.'s earnings per share (EPS)
What is Provectus Biopharmaceuticals, Inc.'s earnings per share (EPS)?
Provectus Biopharmaceuticals, Inc.'s earnings per share (EPS) over the last twelve months is $-0.01, as of Sep 2026.
What was Provectus Biopharmaceuticals, Inc.'s earnings per share (EPS) in 2025?
In 2025, Provectus Biopharmaceuticals, Inc.'s earnings per share (EPS) was $-0.01, compared with $-0.01 in 2024.
How has Provectus Biopharmaceuticals, Inc.'s earnings per share (EPS) changed since 2020?
From 2020 to 2025, Provectus Biopharmaceuticals, Inc.'s earnings per share (EPS) was highest in 2025 ($-0.01) and lowest in 2021 ($-0.02).
How does Provectus Biopharmaceuticals, Inc.'s earnings per share (EPS) compare with similar companies?
Provectus Biopharmaceuticals, Inc.'s earnings per share (EPS) ($-0.01) is higher than that of 3 of the 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with $15.66.